Seeking Alpha

AstraZeneca cleared over Brilinta trial

  • AstraZeneca (NYSE:AZN) says that the U.S. government has closed a probe that investigated a major clinical trial used to win marketing approval for the company's new heart drug Brilinta.
  • Following the DOJ's investigation into the study last October, doubts have ensued over the medicine's future success.
  • AstraZeneca argues that Brilinta can bring in $3.5B in annual sales, although until now the drug has not made any record performance.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs